However, one expert was not sold on this new drug.
"What's most impressive about this two-year clinical trial is how unimpressive it is," said Dr. David L. Katz, director of the Prevention Research Center at Yale University School of Medicine.
Nearly half of the people dropped out in the first year, he pointed out, and by year two, more than half the remainder had also dropped out.
"Among those who remained, lorcaserin produced relatively modest weight loss when combined with diet and exercise counseling, and that weight loss was maintained in over half of the participants only so long as they kept taking the drug. And the paper made no mention of the costs attached to long-term pharmacotherapy," Katz added.
"This close look at lorcaserin reaffirms that better daily use of feet and forks holds far greater promise for meaningful, sustainable and affordable weight control than pharmacotherapy," Katz said.
According to the Associated Press, lorcaserin will be reviewed by an FDA panel in September, and Contrave will be reviewed in December.
For more on losing weight, visit the U.S. National Library of Medicine.
SOURCES: Steven R. Smith M.D., Translational Research Institute for Metabolism and Diabetes, Florida Hospital and Sanford-Burnham, Winter Park, Fla.; Arne Astrup, M.D., department of human nutrition, University of Copenhagen, Denmark; David L. Katz, M.D., M.P.H., director, Prevention Research Center, Yale University School of Medicine, New Haven, Conn.; July 15, 2010, New England Journal of Medicine; Associated Press
All rights reserved